Supportive Care

Jerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.

The rise in survivorship has increased chronic pain in the cancer pain population, the treatment of which has many fundamental differences when compared to acute and terminal cancer pain.

Dr. Maurie Markman discusses how the transition to the new therapeutic paradigm of oral therapies necessitates that we consider unique aspects of this strategy that may negatively impact outcomes compared with an approach of systemic antineoplastic drug administration.

The lack of comprehensive rehabilitation services is a profound source of unnecessary suffering for survivors.

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

Tara Sanft, MD, assistant professor of medicine, director, Survivorship Clinic, Smilow Cancer Hospital at Yale-New Haven, discusses survivorship care plans and how they can differ among patients.

The first FDA-approved biosimilar, Zarxio, has been blocked from reaching US markets by an injunction from Amgen, the manufacturer of the G-CSF analog counterpart, Neupogen (filgrastim).

Treatment with the thrombopoietin receptor agonist eltrombopag significantly improved cytopenias and was well-tolerated in patients with low to intermediate-2 risk myelodysplastic syndromes.

Treatment strategies for patients with myelodysplastic syndromes are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.

Jennifer M. Kapo, MD, chief, palliative medicine, Yale Cancer Center, associate professor of medicine (medical oncology and geriatrics), Yale School of Medicine, discusses how oncologists can address palliative care with their patients.

Interview with Thomas Prebet MD, PhD, in advance of the 2015 International MDS Symposium, on topics related to supportive care in MDS and iron chelation therapy.

Melinda L. Irwin, PhD, MPH, associate professor, Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the results of a study she conducted examining the effects of exercise and weight loss in patients with breast cancer.

Mario E. Lacouture, MD, a dermatologist with Memorial Sloan Kettering Cancer Center, explains how providers can manage adverse events that result from melanoma therapies.

The FDA has approved its first biosimilar, Zarxio, for all five its counterpart Neupogen's authorized indications.

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer specialists and primary care physicians deliver high quality of care to patients with localized disease.

In the United States in 2010, it was estimated that there were more than 1.5 million new cancer cases and 569,490 deaths from cancer.